Objective
With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimers Disease (60% of dementia cases), potentially changing the lives of millions for the better.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesbiological sciencesgeneticsmutation
You need to log in or register to use this function
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
110 Reykjavik
Iceland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.